Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

This work has been supported by the Olivia Hendrickx Research Fund, the Herman Memorial Research Fund, the James E Kearney Memorial Fund and private initiatives. Grants were obtained from ‘Stichting Tegen Kanker’, IWT (TBM projects), the Stem Cell Institute Leuven, the Emmanuel van der Schueren Fund, the International Union Against Cancer, the Klinisch Onderzoeksfonds UZ Leuven and the Fund for Scientific Research – Flanders (FWO-V). S Van Gool is a senior clinical investigator of the FWO-V. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.